MBX (STOCKS)
MBX Biosciences, Inc. Common Stock
$39.000000
+3.490000 (+9.83%)
Prev close: $35.510000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Peter Kent Hawryluk
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,856.30M
- Employees
- 43
- P/E (TTM)
- -17.65
- P/B (TTM)
- 3.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.51 | $-0.59 | +0.0784 | +13.32% |
|
Dec 2025 (Q4)
|
$-0.49 | $-0.62 | +0.1255 | +20.39% |
|
Sep 2025 (Q3)
|
$-0.63 | $-0.70 | +0.0707 | +10.09% |
|
Jun 2025 (Q2)
|
$-0.58 | $-0.77 | +0.1874 | +24.42% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $98.79M |
| Research and Development | $75.23M |
| Other Operating Expenses | $23.56M |
| Operating Income/Loss | -$98.79M |
| Income/Loss From Continuing Operations After Tax | -$86.64M |
| Income/Loss From Continuing Operations Before Tax | -$86.64M |
| Net Income/Loss | -$86.61M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$86.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$86.61M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.16 |
| Diluted Earnings Per Share | -$2.16 |
| Basic Average Shares | 117,038,609 |
| Diluted Average Shares | 117,038,609 |
| Assets | $452.70M |
| Current Assets | $448.54M |
| Cash | $440.00M |
| Other Current Assets | $8.54M |
| Noncurrent Assets | $4.17M |
| Fixed Assets | $3.13M |
| Other Non-current Assets | $1.03M |
| Liabilities | $14.95M |
| Current Liabilities | $14.57M |
| Accounts Payable | $6.97M |
| Other Current Liabilities | $7.59M |
| Noncurrent Liabilities | $378.00K |
| Equity | $437.76M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $437.76M |
| Liabilities And Equity | $452.70M |
| Net Cash Flow From Operating Activities | -$77.48M |
| Net Cash Flow From Operating Activities, Continuing | -$77.48M |
| Net Cash Flow From Investing Activities | -$184.03M |
| Net Cash Flow From Investing Activities, Continuing | -$184.03M |
| Net Cash Flow From Financing Activities | $277.02M |
| Net Cash Flow From Financing Activities, Continuing | $277.02M |
| Net Cash Flow | $15.52M |
| Net Cash Flow, Continuing | $15.52M |
| Comprehensive Income/Loss | -$87.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$87.27M |
| Other Comprehensive Income/Loss | -$22.47M |
| Other Comprehensive Income/Loss Attributable To Parent | -$659.00K |